Misplaced Pages

Bradanicline: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 20:12, 10 August 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,084 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'UNII').← Previous edit Revision as of 20:23, 10 August 2011 edit undoCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[Misplaced Pages:WikiProject Chemicals/ChemNext edit →
Line 1: Line 1:
{{Drugbox| verifiedrevid = 378286631 {{Drugbox| verifiedrevid = 444128206
| |
|IUPAC_name = ''N''-oct-3-yl]-1-benzofuran-2-carboxamide |IUPAC_name = ''N''-oct-3-yl]-1-benzofuran-2-carboxamide
Line 7: Line 7:
| ATC_prefix= | ATC_prefix=
| ATC_suffix= | ATC_suffix=
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = UM3821998K | UNII = UM3821998K
| PubChem= 16727410 | PubChem= 16727410
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank= | DrugBank=
| C=22 | H=23 | N=3 | O=2 | C=22 | H=23 | N=3 | O=2

Revision as of 20:23, 10 August 2011

Pharmaceutical compound
Bradanicline
File:TC-5619.png
Identifiers
IUPAC name
  • N-oct-3-yl]-1-benzofuran-2-carboxamide
PubChem CID
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H23N3O2
Molar mass361.437 g·mol
3D model (JSmol)
SMILES
  • C1CN2CCC1(2CC3=CN=CC=C3)NC(=O)C4=CC5=CC=CC=C5O4
  (verify)

TC-5619 is a drug developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and is currently being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia. Phase I clinical trials have been completed successfully, and it is currently in Phase II trials.

In May 2011, AstraZeneca declined to exercise its right to license the compound.

References

  1. TC-5619 Cognitive Dysfunction in Schizophrenia
  2. Rethinking Schizophrenia
  3. Targacept retains full development rights for TC-5619


Stimulants
Adamantanes
Adenosine antagonists
Alkylamines
Ampakines
Arylcyclohexylamines
Benzazepines
Cathinones
Cholinergics
Convulsants
Eugeroics
Oxazolines
Phenethylamines
Phenylmorpholines
Piperazines
Piperidines
Pyrrolidines
Racetams
Tropanes
Tryptamines
Others
ATC code: N06B

Template:Nootropics

Acetylcholine receptor modulators
Muscarinic acetylcholine receptor modulators
mAChRsTooltip Muscarinic acetylcholine receptors
Agonists
Antagonists
Precursors
(and prodrugs)
See also
Receptor/signaling modulators
Nicotinic acetylcholine receptor modulators
Acetylcholine metabolism/transport modulators
Nicotinic acetylcholine receptor modulators
nAChRsTooltip Nicotinic acetylcholine receptors
Agonists
(and PAMsTooltip positive allosteric modulators)
Antagonists
(and NAMsTooltip negative allosteric modulators)
Precursors
(and prodrugs)
See also
Receptor/signaling modulators
Muscarinic acetylcholine receptor modulators
Acetylcholine metabolism/transport modulators
Categories:
Bradanicline: Difference between revisions Add topic